Abstract
Salivary cortisol sampling has confirmed the presence of increased cortisol secretion in depression and has also revealed that some aspects of hypothalamo-pituitary-adrenal (HPA) axis disturbance have trait-like characteristics that may predict the risk of future illness. Persistent hypersecretion of cortisol in individuals vulnerable to depression also has implications for the medical co-morbidities associated with mood disorder. Pharmacological treatments targeted at the HPA axis represent a novel approach to the management of depression and its complications; however, a better understanding of the molecular basis of HPA axis dysfunction in depressed patients will be needed before this promise can be fulfilled.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
